Management of Metformin in Patients with Fournier's Gangrene
Introduction to Metformin Use in Fournier's Gangrene
- Metformin is not specifically contraindicated in patients with Fournier's gangrene, but should be temporarily discontinued during the acute phase of illness due to the risk of lactic acidosis in critically ill patients, as recommended by the American Journal of Kidney Diseases and Circulation guidelines 1, 2
Contraindications and Precautions for Metformin
- Metformin should be temporarily discontinued during serious intercurrent illnesses that increase the risk of acute kidney injury (AKI), including sepsis, hypotension, dehydration, and major surgery, according to the American Journal of Kidney Diseases guidelines 1
- The American Journal of Kidney Diseases recommends continuing metformin if GFR ≥45 mL/min/1.73m², reviewing use if GFR 30-44 mL/min/1.73m², and discontinuing if GFR <30 mL/min/1.73m² 1, 3
- The following table summarizes the recommendations for metformin use based on GFR:
| GFR (mL/min/1.73m²) | Recommendation |
|---|---|
| ≥45 | Continue metformin |
| 30-44 | Review metformin use |
| <30 | Discontinue metformin |
Management of Metformin in Acute Phase of Fournier's Gangrene
- Temporarily discontinue metformin during the acute phase of Fournier's gangrene due to the risk of AKI from sepsis and hemodynamic instability, and increased risk of lactic acidosis in critically ill patients, as recommended by the American Journal of Kidney Diseases and Circulation guidelines 1, 2
- Metformin can be resumed when the patient is hemodynamically stable, acute infection is controlled, renal function has stabilized at baseline, and there is no evidence of tissue hypoxia or shock, according to the Circulation guidelines 2
Alternative Diabetes Medications and Monitoring
- Insulin is typically the preferred agent for glycemic control during acute illness, and DPP-4 inhibitors may be considered in less severe cases with stable renal function, as suggested by the Circulation guidelines 2
- The following DPP-4 inhibitors require dose adjustments in renal impairment:
| DPP-4 Inhibitor | Dose Adjustment |
|---|---|
| Sitagliptin | Downward adjustment |
| Saxagliptin | Downward adjustment |
| Vildagliptin | Downward adjustment |
| Linagliptin | No adjustment needed |
- Monitor for complications, including signs of lactic acidosis, deterioration in renal function, and worsening sepsis, although the specific guidelines for monitoring are not provided 2
- Patients who have used metformin long-term should be watched for symptoms of vitamin B12 deficiency, as stated in Diabetes Care 5
- Impaired renal function (eGFR <45 mL/min/1.73 m²) is a primary risk factor for metformin-associated lactic acidosis, as stated by the American Journal of Kidney Diseases and The Lancet Diabetes and Endocrinology 4, 6
- The benefits of metformin in reducing cardiovascular events and mortality in patients with type 2 diabetes generally outweigh the risk of lactic acidosis when used appropriately, with a moderate to high strength of evidence, as stated by the Circulation journal 2
- In cases of lactic acidosis, the Kidney International guidelines recommend immediate discontinuation of metformin, prompt hemodialysis or continuous renal replacement therapy, and supportive care, including hemodynamic support and ventilation if needed 7
- More frequent monitoring (every 3-6 months) of renal function is recommended for patients with eGFR <60 mL/min/1.73 m², as suggested by Praxis Medical Insights and the Kidney International guidelines 8, 7